Anti-CD30 (Brentuximab Vedotin), Chimeric AntibodyDatasheet
|Synonyms:||cAC10-vcMMAE, SGN 35, SGN-35, Ki-1, D1S166E, TNFRSF8|
The research-grade biosimilar is an antibody-drug conjugate that targets CD30. The conjugate consists of an Anti-CD30 human-mouse chimeric IgG1 antibody that is linked to a microtubule disrupting agent monomethyl auristatin E (MMAE) via a protease-cleavable linker. Upon internalization in the cell, the MMAE is detached from the antibody due to proteolytic cleavage. The MMAE then disrupts the microtubule network, which causes cell cycle arrest and results in apoptosis of tumorigenic cells. The original drug received approval from the FDA to treat adult patients with relapsed or refractory Hodgkin’s lymphoma and systemic anaplastic large cell lymphoma.